Table 4. Univariate and multivariate analysis for cardiac event-free duration.
| Cardiac event-free duration | ||||||
|---|---|---|---|---|---|---|
| Univariate analysis | Multivariate analysis | |||||
| HR | 95% CI | p-value | HR | 95% CI | p-value | |
| Age (yr) | - | - | - | |||
| < 55 | 1 | |||||
| ≥ 55 | 1.350 | 0.571–3.192 | 0.494 | |||
| Hypertension | ||||||
| No | 1 | 1 | ||||
| Yes | 1.938 | 0.780–4.813 | 0.154 | 1.961 | 0.787–4.887 | 0.148 |
| DM | - | - | - | |||
| No | 1 | |||||
| Yes | 1.751 | 0.641–4.781 | 0.275 | |||
| Overweight | - | - | - | |||
| No | 1 | |||||
| Yes | 0.536 | 0.156–1.836 | 0.321 | |||
| Hyperlipidemia | - | - | - | |||
| No | 1 | |||||
| Yes | 0.807 | 0.271–2.401 | 0.700 | |||
| Smoking | - | - | - | |||
| No | 1 | |||||
| Yes | 1.423 | 0.419–4.832 | 0.572 | |||
| Radiation | - | - | - | |||
| No | 1 | |||||
| Yes | 1.906 | 0.698–5.204 | 0.208 | |||
| Regimen | ||||||
| AC+T | 1 | 1 | ||||
| AC+T with docetaxel | 2.048 | 0.794–5.283 | 0.138 | 2.524 | 0.973–6.547 | 0.057 |
| Baseline LVEF | ||||||
| ≥ 60% | 1 | 1 | ||||
| < 60% | 2.147 | 0.786–5.865 | 0.136 | 1.838 | 0.665–5.077 | 0.241 |
| Dexrazoxane use | ||||||
| No | 1 | 1 | ||||
| Yes | 0.128 | 0.017–0.953 | 0.045 | 0.119 | 0.016–0.904 | 0.040 |
HR=hazard ratio; CI=confidence interval; DM=diabetes mellitus; AC+T=doxorubicin with cyclophosphamide+trastuzumab; LVEF=left ventricular ejection fraction.